[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:malignant-neoplasm-of-biliary-tract:hepatitis-b-infection":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"Malignant neoplasm of biliary tract","Hepatitis B Infection",3,[8,16,22],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07433673","Gemcitabine, Cisplatin, Nab-paclitaxel (GAP) and Cemiplimab for Locally Advanced Biliary Tract Cancer (BTC)",[12],"Phase 2","RECRUITING","2026-08-26T02:19:08.084946Z","2026-05-05T02:43:29.707381Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT06001658","Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers",[12],"2026-08-26T02:15:47.754948Z","2026-05-05T02:43:27.840351Z",{"nct_id":23,"title":24,"phases":25,"status":26,"updated_at":27,"content_modified":28},"NCT03482102","Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer",[12],"ACTIVE_NOT_RECRUITING","2026-08-03T03:53:05.241597Z","2026-05-05T02:43:26.965263Z"]